OpenEvidence just doubled its valuation in three months. The medical AI platform announced a $250 million Series D at $12 billion on Wednesday, co-led by Thrive Capital and DST Global, barely three months after raising at a $6 billion valuation. The funding sprint signals that venture capitalists aren't sweating competition from OpenAI and Anthropic's newly launched health products, betting instead that specialized medical platforms will carve out their own turf.
The speed of OpenEvidence's ascent is the real story here. Three months ago, the medical database startup was valued at $6 billion. Today it's at $12 billion. That's the kind of velocity you typically see in breakthrough consumer apps or infrastructure plays, not specialized B2B healthcare platforms. Yet here we are.
The Series D announcement landed Wednesday, with Thrive Capital and DST Global leading the $250 million round. The company has now raised $700 million total, pulling in support from heavy hitters like Sequoia Capital, Nvidia, Kleiner Perkins, Blackstone, Bond, and Craft Ventures. Even Mayo Clinic backed them, which tells you something about the credibility they've built with the actual medical establishment.
So what's driving this frenzy? The usage numbers are pretty jaw-dropping. OpenEvidence says its free, ad-supported platform handled 18 million clinical consultations from verified healthcare professionals in the U.S. in December alone. Compare that to just 3 million monthly searches a year ago. That's a six-fold increase year-over-year. They've also crossed $100 million in revenue.
The platform itself is basically a modern medical reference engine purpose-built for doctors. Think of it as what WebMD was to the early internet, but instead of hypochondriacs googling their symptoms, it's physicians hunting for treatment guidance, drug interactions, and clinical evidence during patient consultations. The distinction matters because it means OpenEvidence operates in a different lane than the consumer health AI products that OpenAI unveiled last week or the Claude for Healthcare tool that Anthropic just launched.
This is worth noting because when those announcements dropped, the immediate reaction in some quarters was panic. The thinking went: if OpenAI and Anthropic are launching health features, doesn't that tank the value of specialized health startups? The funding round is basically VCs saying "no, not really." There's room for both. Anthropic's Claude for Healthcare targets patients, payers, and providers broadly. ChatGPT Health is consumer-focused. OpenEvidence is drilling deep into the actual clinical workflow - the moment a doctor needs to look something up while treating a patient.
The market opportunity is genuinely massive. There are roughly 1 million active physicians in the U.S. alone, and they're drowning in information overload during patient visits. If OpenEvidence can own the medical reference layer the way Google owns search or Shopify owns commerce infrastructure, the unit economics look incredible. An ad-supported model might seem quaint compared to enterprise SaaS, but when you're talking 18 million consultations monthly from verified professionals, that's a profitable business already.
What's particularly interesting is the investor makeup. Thrive Capital, led by Joshua Kushner, has become a serious health tech player over the past few years. DST Global is Yuri Milner's vehicle, and DST has shown it will write enormous checks for high-growth platforms regardless of vertical. The fact that both are comfortable with the $12 billion valuation suggests they see something beyond the current financial metrics - they're betting on OpenEvidence becoming mission-critical infrastructure in healthcare, the kind of thing that eventually gets acquired by health systems, EMR companies, or maybe even rolled into a broader enterprise health platform.
The timing also matters. Healthcare is spending more on AI than almost any other sector right now. Hospitals are scrambling to figure out how to integrate AI into workflows without completely breaking existing systems. A platform that works in the doctor's current workflow, delivering evidence-based guidance without requiring a total rebuild of how medicine gets practiced, becomes very valuable very quickly.
OpenEvidence's funding blitz reflects a growing conviction among top-tier VCs that the future of healthcare AI isn't one-size-fits-all consumer products from AI labs, but specialized, workflow-integrated tools built for professionals who actually practice medicine. The platform's growth metrics and willingness from serious institutional investors like Thrive and DST to nearly double the valuation in 90 days suggests the company has found something sticky - a product doctors actually use multiple times daily that's growing faster than anyone expected. In a market where OpenAI and Anthropic are throwing resources at health as a new frontier, OpenEvidence is proving that vertical specialization and real clinical utility might matter more than brand recognition.
